Form 8-K - Current report:
SEC Accession No. 0000950170-24-126734
Filing Date
2024-11-14
Accepted
2024-11-14 07:15:08
Documents
13
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K itrm-20241114.htm   iXBRL 8-K 39960
2 EX-99.1 itrm-ex99_1.htm EX-99.1 203422
3 GRAPHIC img185001215_0.jpg GRAPHIC 8020
  Complete submission text file 0000950170-24-126734.txt   386364

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT itrm-20241114.xsd EX-101.SCH 26763
15 EXTRACTED XBRL INSTANCE DOCUMENT itrm-20241114_htm.xml XML 4891
Mailing Address FITZWILLIAM COURT, 1ST FLOOR LEESON CLOSE DUBLIN 2 L2 D02 YW24
Business Address FITZWILLIAM COURT, 1ST FLOOR LEESON CLOSE DUBLIN 2 L2 D02 YW24 (872) 225-6077
Iterum Therapeutics plc (Filer) CIK: 0001659323 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38503 | Film No.: 241457161
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)